Entasis Therapeutics Holdings Inc. (ETTX) financial statements (2020 and earlier)

Company profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:4185
Cash and cash equivalents1649
Short-term investments2536
Other undisclosed cash, cash equivalents, and short-term investments00
Receivables12
Prepaid expense5 
Other current assets2 
Other undisclosed current assets(0)2
Total current assets:4989
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment00
Other noncurrent assets00
Total noncurrent assets:20
TOTAL ASSETS:5189
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54
Accounts payable11
Accrued liabilities11
Employee-related liabilities22
Debt1 
Other undisclosed current liabilities22
Total current liabilities:86
Noncurrent Liabilities
Long-term debt and lease obligation1 
Operating lease, liability1
Liabilities, other than long-term debt 0
Deferred rent credit 0
Total noncurrent liabilities:10
Total liabilities:96
Stockholders' equity
Stockholders' equity attributable to parent4283
Common stock00
Additional paid in capital176173
Accumulated other comprehensive loss (0)
Accumulated deficit(134)(90)
Total stockholders' equity:4283
TOTAL LIABILITIES AND EQUITY:5189

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:75
Operating expenses(54)(43)
Operating loss:(47)(38)
Other undisclosed income from continuing operations before equity method investments, income taxes46
Loss from continuing operations before income taxes:(43)(32)
Income tax expense(1)(0)
Net loss attributable to parent:(44)(33)
Undistributed earnings (loss) allocated to participating securities, basic (9)
Net loss available to common stockholders, diluted:(44)(42)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(44)(33)
Comprehensive loss:(44)(33)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(44)(33)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: